Syremis Therapeutics, a Tel Aviv, Israel, and Boston, USA-based clinical-stage biopharma developing novel medicines to make a ...

California, USA-based Vistagen yesterday announced that the PALISADE-3 Phase III study of intranasal fasedienol for the acute ...

An Expert View piece looking forward to next year from the global strategy consultancy's Simon Middleton, head, Europe Life ...

US healthcare giant Johnson & Johnson announced that the US Food and Drug Administration (FDA) approved Rybrevant Fasbro ...

US pharma Viatris (Nasdaq: VTRS) has logged four regulatory milestones across its global pipeline, spanning a US Food and ...

US biotech Cytokinetics (Nasdaq: CYTK) has secured the first global approval for its cardiac myosin inhibitor aficamten, ...

RNAi therapeutics company Alnylam Pharmaceuticals has announced the planned expansion of its manufacturing facility in Norton ...

US biotech VYNE Therapeutics has agreed to merge with privately held Yarrow Bioscience in an all-stock transaction, pivoting ...

Cambridge, USA-based CAMP4 Therapeutics has entered into a strategic research, collaboration and license agreement with UK ...

UK pharma major GSK yesterday announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

Japanese drugmaker Takeda has announced positive topline results for two pivotal Phase III studies of zasocitinib (TAK-279), ...

US biopharma Insmed Incorporated has announced that the Phase IIb BiRCh study of brensocatib in chronic rhinosinusitis ...